Fri, Jul 16, 2021

Will the APAC Life Sciences Sector Get a Shot in the Arm in the Post�COVID-19 Era?

Duff & Phelps, A Kroll business recently hosted a webinar on July 7, 2021 on valuation, M&A, business risks and growth strategy in the healthcare and life sciences (HLS) industry.

Webcast Replay | Will the APAC Life Sciences Sector Get a Shot in the Arm in the Post-COVID-19 Era?

Duration: 1 hour 15 minutes

Download Webcast Slides

Topics

Setting the Context

  • Recent industry highlights and key discussion points

Deal Trends and Investment Opportunities

  • A practitioners perspective on growth strategies of pharmaceutical companies and their use of M&A to “scale up”
  • Key long-term investment trends and their impact on deals
  • Key sub-sectors where we expect to see M&A activity
  • Valuation multiples - key considerations, dilemmas in the APAC HLS space
  • APAC HLS landscape since COVID-19 outbreak

Evolving Reputation and Governance Risks in HLS Industry

  • Challenges in the COVID-19 times for HLS companies in the region
  • Emerging risks amidst strong growth opportunities
  • Supply chain vulnerabilities and mitigation

Guest Speaker

  • Kedar Upadhye, Global CFO, Cipla Limited

Kroll Speaker



Valuation Advisory Services

Our valuation experts provide valuation services for financial reporting, tax, investment and risk management purposes.

Valuation Services

When companies require an objective and independent assessment of value, they look to Kroll.